- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about AZNCF
Recent news which mentions AZNCF
AstraZeneca Forecasts Growth In 2023 Earnings, Revenue Despite Fall In COVID-19 Products, Plans To Deliver 15 New Medicines This Decade
February 09, 2023
From Benzinga
International stocks can help improve your returns. This highly rated fund can offer good diversity for your portfolio.
February 06, 2023
From MarketWatch
From Benzinga
From Benzinga
AstraZeneca's Current Valuation Not Reflective Of Its Strong Fundamentals, Analyst Says
January 05, 2023
From Benzinga
Europe Approves AstraZeneca's Two Combo Therapies For Prostate, Bile Duct Cancer Settings
December 21, 2022
From Benzinga
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
December 19, 2022
From Benzinga
From Benzinga
From Benzinga
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
December 09, 2022
From Benzinga
AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials
December 08, 2022
From Benzinga
AstraZeneca's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer
December 07, 2022
From Benzinga
AstraZeneca Bets On UK Listed Firm For Lung Diseases
November 28, 2022
From Benzinga
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
November 16, 2022
From Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
November 14, 2022
From Benzinga
From Benzinga
AstraZeneca Ditches US Application Submission For COVID-19 Shot, Q3 Edges Analyst Expectations On Oncology Strength
November 10, 2022
From Benzinga
FDA Adcomm Backs AstraZeneca's 2-In-1 Asthma Inhaler, Only For Adults Being Less Sure For Adolescents, Kids
November 09, 2022
From Benzinga
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
November 04, 2022
From Benzinga
From Benzinga
AstraZeneca's Ultomiris Showed Zero Relapses In Patients With Chronic Disorder Of Brain, Spinal Cord
October 27, 2022
From Benzinga
AstraZeneca Touts Positive Data From Two Experimental Drugs In Breast Cancer Settings
October 26, 2022
From Benzinga
AstraZeneca's Fasenra Flunks Late-Stage Trial In Patients With Esophagus Inflammation
October 25, 2022
From Benzinga
AstraZeneca's Imfinzi Combo Scores FDA Approval For Liver Cancer
October 24, 2022
From Benzinga
From Benzinga
From Benzinga
Why Are LogicBio Therapeutics Shares Skyrocketing Today?
October 03, 2022
From Benzinga
Japan Approves AstraZeneca's Two Treatments For Asthma, Rare Form Of Cancer
September 27, 2022
From Benzinga
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
September 23, 2022
From Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
September 21, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.